Tempus AI (NASDAQ:TEM) Coverage Initiated at Mizuho

Equities research analysts at Mizuho assumed coverage on shares of Tempus AI (NASDAQ:TEM) in a research note issued on Thursday, MarketBeat reports. The brokerage set an “outperform” rating and a $100.00 price target on the stock. Mizuho’s price target would indicate a potential upside of 71.32% from the company’s current price.

Other equities research analysts have also issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Robert W. Baird initiated coverage on shares of Tempus AI in a report on Tuesday. They issued an “outperform” rating and a $59.00 price objective for the company. Needham & Company LLC lifted their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. BTIG Research increased their target price on Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Finally, JPMorgan Chase & Co. reduced their price target on Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Tempus AI presently has a consensus rating of “Hold” and an average target price of $85.92.

Tempus AI Trading Down 2.7%

NASDAQ TEM opened at $58.37 on Thursday. The business has a fifty day simple moving average of $62.35 and a 200 day simple moving average of $73.39. The firm has a market capitalization of $10.38 billion, a P/E ratio of -49.05 and a beta of 5.22. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI has a 12 month low of $36.22 and a 12 month high of $104.32.

Insider Activity at Tempus AI

In related news, CFO James William Rogers sold 19,966 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $73.20, for a total value of $1,461,511.20. Following the sale, the chief financial officer directly owned 111,250 shares of the company’s stock, valued at $8,143,500. This trade represents a 15.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Andrew Polovin sold 12,874 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $75.00, for a total transaction of $965,550.00. Following the sale, the executive vice president owned 107,590 shares in the company, valued at approximately $8,069,250. This trade represents a 10.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 775,159 shares of company stock valued at $50,789,800 in the last ninety days. 26.27% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently modified their holdings of the company. GC Wealth Management RIA LLC purchased a new position in shares of Tempus AI during the 4th quarter valued at about $399,267,000. Vanguard Group Inc. boosted its stake in Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after buying an additional 1,706,837 shares in the last quarter. Voloridge Investment Management LLC grew its position in Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after acquiring an additional 1,039,176 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Tempus AI by 312.7% during the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock worth $102,869,000 after acquiring an additional 965,730 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Tempus AI in the 2nd quarter worth approximately $54,020,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.